Stryker Corporation
$141.0M 168,381 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. reported $148,896,583.35 across General Payments, Research, and Ownership to 216,716 physicians and teaching hospitals across 218,635 transactions.
- $148.9M Top 1% payer
- All-tracks total
- 218,635 Top 1% volume
- Transactions
- 216,716 Top 1% reach
- Recipients
- −$1.3M
- General Payments vs PY2023
Boehringer Ingelheim Pharmaceuticals, Inc. reported $148,896,583.35 across all CMS Open Payments tracks (General + Research + Ownership) to 216,716 physicians and teaching hospitals in Program Year 2024 - ranking #17 of 1,925 reporting manufacturers (1.1% of the all-tracks industry total); General Payments alone were $17,859,513.38, averaging $687.06 per recipient.
How Boehringer Ingelheim Pharmaceuticals, Inc.'s $148.9M all-tracks total breaks down
Boehringer Ingelheim Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
100/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer boehringer-ingelheim-pharmaceuticals-inc Boehringer Ingelheim Pharmaceuticals, Inc.
$148.9M · #17/1,925 · 1.1% industry · PY2024
- TOT $148.9M
- RANK #17
- SHARE 1.1%
- TXN 218,635
- RCP 216,716
- CAT 8
- GEN $17.9M
- ΔGEN −$1.3M
- TOP1 3.6%
- PY 2024
Volume peers
Nearest volume peer: Stryker Corporation ($141.0M)
Boehringer Ingelheim Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Boehringer Ingelheim Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $1.3M (−6.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.PY2023: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.PY2024: Boehringer Ingelheim Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $19,143,070.27
- PY2024
- $17,859,513.38
What the Data Shows for Boehringer Ingelheim Pharmaceuticals, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Boehringer Ingelheim Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
3,439 transactions worth $7.1M make "Compensation for Services Other Than Consulting" the top general-payment category in the 8-category breakdown below, 39.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 8 types of general payments, Boehringer Ingelheim Pharmaceuticals, Inc.'s largest category was "Compensation for Services Other Than Consulting" at $7.1M - 39.5% of General Payments.
Boehringer Ingelheim Pharmaceuticals, Inc. reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (39.5%), Food and Beverage (28.2%), and Consulting Fee (18.4%). The remaining 5 categories make up 13.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Boehringer Ingelheim Pharmaceuticals, Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Boehringer Ingelheim Pharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $7.1M | 3,439 | 39.5% |
| Food and Beverage | $5.0M | 209,184 | 28.2% |
| Consulting Fee | $3.3M | 611 | 18.4% |
| Travel and Lodging | $962.8K | 3,099 | 5.4% |
| Grant | $567.1K | 14 | 3.2% |
| Royalty or License | $521.4K | 8 | 2.9% |
| Space Rental or Facility Fees | $423.5K | 177 | 2.4% |
| Education | $6.4K | 184 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,786,867.80 (10.0%) of $17,859,513.38 in this company's General Payments records across 75,079 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Boehringer Ingelheim Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Russell Lee Carlisle
$642,009.64 across 11 reported transactions
- 2
Hospital Of The Univ Of Penna
$520,426.71 across 12 reported transactions
- 3
Univ Of Mi Hospitals & Hlth Ctrs
$288,636.64 across 10 reported transactions
- 4
University Of Washington Med Ctr
$187,794.81 across 6 reported transactions
- 5
Beth Israel Deaconess Medical Center
$148,000.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Boehringer Ingelheim Pharmaceuticals, Inc. ranks #17 of 1,925 by total payments (top 1% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,789 of 1,838 by HHI (bottom 3% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Teva Pharmaceuticals USA, Inc. : $13.9M total payments, HHI 40
- American Orthodontics Corporation : $374.7K total payments, HHI 38
- Impel Pharmaceuticals LLC : $15.8K total payments, HHI 36
- Ultradent Products Inc : $1.8M total payments, HHI 36
- OWP Pharmaceuticals, Inc. : $7.8K total payments, HHI 35
- Dilon Technologies, Inc. : $148.5K total payments, HHI 35
- Boehringer Ingelheim Pharmaceuticals, Inc. (this company) : $17.9M total payments, HHI 34
- Inspire Medical Systems, Inc. : $3.9M total payments, HHI 34
- Hologic Sales and Service, LLC : $1.2M total payments, HHI 33
- CooperVision Inc. : $2.5M total payments, HHI 33
- AngioDynamics, Inc. : $17.3M total payments, HHI 33
- Otsuka America Pharmaceutical, Inc. : $14.5M total payments, HHI 33
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Boehringer Ingelheim Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Boehringer Ingelheim Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Boehringer Ingelheim Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
AstraZeneca UK Limited
$124.7M 2,367 recipients
Compare payment profiles
Regeneron Pharmaceuticals, Inc.
$123.5M 5,932 recipients
Compare payment profiles
Sanofi US Services Inc.
$114.0M 478 recipients
Compare payment profiles
Edge Endo LLC
$113.4M 40 recipients
Compare payment profiles
Trimed, Inc.
$111.0M 2,318 recipients
Compare payment profiles
Put this to use
Boehringer Ingelheim Pharmaceuticals, Inc. ranks #17 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Boehringer Ingelheim Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Boehringer Ingelheim Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.